Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arsenic Trioxide + Cyclophosphamide in Relapsed/Refractory AML
NCT03318016Phase 1Terminated
- Sponsor
- University of Colorado Denver
- Start
- Dec 2017
- Primary completion
- Jan 2020
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 1, open-label trial of arsenic trioxide in acute myeloid leukemia (AML) (5 cohorts), sponsored by University of Colorado Denver. Primary endpoint: Maximum Tolerated Dose at 26 months. Started Dec 2017; status: terminated.
02
Drugs
arsenic trioxide
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03318016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03318016.